EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access

The Pharmacologic inhibition of KRAS mutants as a treatment for cancer: Therapeutic principles and clinical results

Stefan Kasper, Martin Sebastian

Deutsches Ärzteblatt international · 2025

DOI: 10.3238/arztebl.m2025.0002 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Deutsches Ärzteblatt international, 2025. Verfasst von Stefan Kasper und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, West German Cancer Center, University Hospital Essen; Department of Medicine III, Hematology/Oncology, Rheumatology, …. Hauptthemen laut MEDLINE: Proto-Oncogene Proteins p21(ras), Antineoplastic Agents, Pyrimidines, Neoplasms. Die Arbeit nennt 31 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Mutations of the KRAS oncogene are found in up to 20% of all cancers, and particularly in non-small-cell lung cancer (NSCLC) (20-40%) and colorectal cancer (CRC) (30-50%). Inhibitors of specific KRAS mutants have recently become available and are now a part of routine care. METHODS: This review is based on articles published in the past 5 years that were retrieved by a selective search in PubMed for clinical trials of the pharmacological inhibition of KRAS. RESULTS: Sotorasib and adagrasib have already been approved, on the basis of two randomized phase III trials, as specific inhibitors of the KRASG12C mutant for palliative second-line treatment. Compared to standard chemotherapy with docetaxel, both drugs significantly prolonged progression-free survival (PFS): 5.6 months (95% confidence interval [4.3; 7.8]) for sotorasib versus 4.5 [3.0; 5.7] for docetaxel, and 5.5 months [4.5; 6.7] for adagrasib versus 3.8 [2.7; 4.7] for docetaxel. Sotorasib was also found to cause fewer severe adverse drug events (33%, versus 40% with docetaxel). The most common ones were diarrhea and elevated liver enzymes. For already treated CRC, sotorasib combined with the anti-epidermal growth factor receptor (anti-EGFR) antibody panitumumab was found, in a randomized phase III trial, to prolong progression-free survival significantly compared to standard therapy with triflurdin/tipiracil or regorafenib (5.6 months [4.2; 6.3] versus 2.2 months [1.9; 3.9]), while also improving patients' quality of life. Approval by the European Medicines Agency is pending. Further KRAS and pan-RAS inhibitors are now in early clinical development. CONCLUSION: Pharmacological KRAS inhibition is a promising new approach to the treatment of many kinds of cancer.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Proto-Oncogene Proteins p21(ras)Antineoplastic AgentsPyrimidinesNeoplasmsHumansMutationPiperazinesColorectal NeoplasmsTreatment OutcomeLung NeoplasmsCarcinoma, Non-Small-Cell LungAcetonitrilesPyridines

Substanzen

Proto-Oncogene Proteins p21(ras)sotorasibAntineoplastic AgentsPyrimidinesKRAS protein, humanadagrasibPiperazinesAcetonitrilesPyridines

Autor:innen und Institutionen

  • Department of Medical Oncology, West German Cancer Center, University Hospital Essen; Department of Medicine III, Hematology/Oncology, Rheumatology, Infectious Diseases, HIV, University Hospital Frankfurt.

Zitieren

APA

Kasper, S., & Sebastian, M. (2025). The Pharmacologic inhibition of KRAS mutants as a treatment for cancer: Therapeutic principles and clinical results. Deutsches Ärzteblatt international. https://doi.org/10.3238/arztebl.m2025.0002

Vancouver

Kasper S, Sebastian M. The Pharmacologic inhibition of KRAS mutants as a treatment for cancer: Therapeutic principles and clinical results. Deutsches Ärzteblatt international. 2025. doi:10.3238/arztebl.m2025.0002

BibTeX
@article{Kasper2025,
  author = {Kasper, Stefan and Sebastian, Martin},
  title = {The Pharmacologic inhibition of KRAS mutants as a treatment for cancer: Therapeutic principles and clinical results},
  journal = {Deutsches Ärzteblatt international},
  year = {2025},
  doi = {10.3238/arztebl.m2025.0002}
}
Kostenlos starten →